BidaskClub cut shares of FibroGen (NASDAQ:FGEN) from a hold rating to a sell rating in a research note issued to investors on Thursday.

Other equities analysts also recently issued research reports about the company. Stifel Nicolaus restated a buy rating and issued a $80.00 price objective on shares of FibroGen in a report on Thursday, September 14th. Jefferies Group restated a buy rating and issued a $75.00 price objective on shares of FibroGen in a report on Tuesday, September 12th. Mizuho restated a hold rating and issued a $61.00 price objective on shares of FibroGen in a report on Thursday, November 9th. William Blair restated an outperform rating on shares of FibroGen in a report on Wednesday, August 9th. Finally, ValuEngine downgraded FibroGen from a hold rating to a sell rating in a report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. FibroGen has an average rating of Buy and a consensus price target of $65.67.

Shares of FibroGen (NASDAQ FGEN) traded up $1.15 on Thursday, hitting $46.40. The stock had a trading volume of 662,827 shares, compared to its average volume of 617,430. FibroGen has a one year low of $19.25 and a one year high of $60.15. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.83 and a current ratio of 10.83.

In other FibroGen news, VP Pat Cotroneo sold 2,851 shares of the stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $49.45, for a total transaction of $140,981.95. Following the transaction, the vice president now owns 157,405 shares in the company, valued at $7,783,677.25. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Thomas F. Kearns, Jr. sold 18,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $45.22, for a total value of $813,960.00. Following the transaction, the director now owns 156,564 shares in the company, valued at approximately $7,079,824.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 399,982 shares of company stock worth $21,250,362. Corporate insiders own 13.60% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of FGEN. FMR LLC boosted its position in shares of FibroGen by 96.9% in the second quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock valued at $107,753,000 after acquiring an additional 1,641,423 shares during the period. EcoR1 Capital LLC boosted its position in shares of FibroGen by 3,674.1% in the second quarter. EcoR1 Capital LLC now owns 1,585,457 shares of the biopharmaceutical company’s stock valued at $51,210,000 after acquiring an additional 1,543,448 shares during the period. Janus Henderson Group PLC bought a new stake in shares of FibroGen in the second quarter valued at approximately $45,633,000. Eagle Asset Management Inc. bought a new stake in shares of FibroGen in the third quarter valued at approximately $46,158,000. Finally, Vanguard Group Inc. boosted its position in shares of FibroGen by 15.1% in the second quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock valued at $187,612,000 after acquiring an additional 761,421 shares during the period. 57.42% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/12/08/fibrogen-fgen-downgraded-to-sell-at-bidaskclub.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.